Search research articles
Contact Us
Filters
Showing results (201-210 of 234) with videos related to
Page
of 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2019
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Deepak Perumal, Naoko Imai, Alessandro Laganà, et al.
Blood
|
November 3, 2011
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H Kim, Dita Gratzinger, Cameron Harrison, et al.
Cancer Discovery
|
December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Ranjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
Nature Medicine
|
December 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
Haematologica
|
November 28, 2024
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma
Lorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, et al.
Biorxiv : the Preprint Server for Biology
|
October 3, 2025
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors
Matthew J Lin, Joanna K Chorazeczewski, Gvantsa Pantsulaia, et al.
Leukemia & Lymphoma
|
November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
John Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Blood
|
January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua D Brody, Judit Jørgensen, David Belada, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
April 4, 2025
Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation
Xucheng Hou, Chang Wang, Yichen Zhong, et al.
The Journal of Infectious Diseases
|
April 4, 2026
Cefazolin inoculum effect and cefazolin microbiological treatment failure in serious methicillin-susceptible Staphylococcus aureus infections: A multi-center retrospective cohort study
Mitchell A Jeffs, Nicole Li, Oluwalade Ogunkoya, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 234) with videos related to
Sort By:
Page
of 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2019
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Deepak Perumal, Naoko Imai, Alessandro Laganà, et al.
Blood
|
November 3, 2011
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H Kim, Dita Gratzinger, Cameron Harrison, et al.
Cancer Discovery
|
December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Ranjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
Nature Medicine
|
December 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
Haematologica
|
November 28, 2024
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma
Lorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, et al.
Biorxiv : the Preprint Server for Biology
|
October 3, 2025
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors
Matthew J Lin, Joanna K Chorazeczewski, Gvantsa Pantsulaia, et al.
Leukemia & Lymphoma
|
November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
John Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Blood
|
January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua D Brody, Judit Jørgensen, David Belada, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
April 4, 2025
Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation
Xucheng Hou, Chang Wang, Yichen Zhong, et al.
The Journal of Infectious Diseases
|
April 4, 2026
Cefazolin inoculum effect and cefazolin microbiological treatment failure in serious methicillin-susceptible Staphylococcus aureus infections: A multi-center retrospective cohort study
Mitchell A Jeffs, Nicole Li, Oluwalade Ogunkoya, et al.
Page
of 24